- Home
- ADCT vs AGL Comparison
ADCT vs AGL Comparison
Compare ADCT & AGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- AGL
- Stock Information
- Founded
- ADCT 2011
- AGL 2016
- Country
- ADCT Switzerland
- AGL United States
- Employees
- ADCT N/A
- AGL N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- AGL Managed Health Care
- Sector
- ADCT Health Care
- AGL Health Care
- Exchange
- ADCT Nasdaq
- AGL Nasdaq
- Market Cap
- ADCT 380.2M
- AGL 401.9M
- IPO Year
- ADCT 2020
- AGL 2021
- Fundamental
- Price
- ADCT $3.95
- AGL $0.76
- Analyst Decision
- ADCT Strong Buy
- AGL Hold
- Analyst Count
- ADCT 6
- AGL 20
- Target Price
- ADCT $7.60
- AGL $2.75
- AVG Volume (30 Days)
- ADCT 860.1K
- AGL 8.0M
- Earning Date
- ADCT 11-10-2025
- AGL 11-04-2025
- Dividend Yield
- ADCT N/A
- AGL N/A
- EPS Growth
- ADCT N/A
- AGL N/A
- EPS
- ADCT N/A
- AGL N/A
- Revenue
- ADCT $77,246,000.00
- AGL $5,901,182,000.00
- Revenue This Year
- ADCT $11.78
- AGL N/A
- Revenue Next Year
- ADCT $4.83
- AGL $5.76
- P/E Ratio
- ADCT N/A
- AGL N/A
- Revenue Growth
- ADCT 15.73
- AGL 11.76
- 52 Week Low
- ADCT $1.05
- AGL $0.71
- 52 Week High
- ADCT $4.80
- AGL $6.08
- Technical
- Relative Strength Index (RSI)
- ADCT 44.05
- AGL 30.66
- Support Level
- ADCT $3.92
- AGL $0.72
- Resistance Level
- ADCT $4.80
- AGL $1.03
- Average True Range (ATR)
- ADCT 0.23
- AGL 0.07
- MACD
- ADCT -0.06
- AGL -0.01
- Stochastic Oscillator
- ADCT 4.32
- AGL 6.44
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.